Article Details

Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara

Retrieved on: 2023-12-02 00:11:42

Tags for this article:

Click the tags to see associated articles and topics

Samsung Bioepis Secures US License Date for SB17, a Proposed Biosimilar to Stelara. View article details on hiswai:

Excerpt

Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo